Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 4/20 | 0.44 |
| ▸ | MERTK | Q12866 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | EPAS1 | Q99814 | 4/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.35 |
| ▸ | VEGFA | P15692 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4268207 | 0.92 | VCAM1 (0.42) | VCAM1MERTKCYP3A4KCNH2EPAS1 | |
| SCHEMBL3035964 | 0.90 | CYP3A4 (0.48) | VCAM1MERTKCYP3A4KCNH2EPAS1 | |
| SCHEMBL3636393 | 0.88 | MAPT (0.39) | VCAM1MERTKMAPTHSPB1 | |
| SCHEMBL3638340 | 0.85 | VCAM1 (0.36) | VCAM1MERTKEPAS1MAPTHSPB1 | |
| SCHEMBL1194672 | 0.85 | EPAS1 (0.37) | VCAM1MERTKEPAS1MAPTHSPB1 | |
| SCHEMBL4754814 | 0.84 | CYP3A4 (0.44) | VCAM1MERTKCYP3A4KCNH2EPAS1 | |
| SCHEMBL3642200 | 0.84 | CYP3A4 (0.39) | VCAM1MERTKCYP3A4KCNH2EPAS1 | |
| SCHEMBL3027860 | 0.84 | CYP3A4 (0.44) | VCAM1MERTKCYP3A4KCNH2EPAS1 | |
| SCHEMBL3642203 | 0.84 | CYP3A4 (0.39) | VCAM1MERTKCYP3A4KCNH2EPAS1 | |
| SCHEMBL3031375 | 0.81 | EPAS1 (0.40) | VCAM1EPAS1MAPTHSPB1VEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304419-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304419-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304419-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-26 | — | — | US | disclosed |
| EP-2166856-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2010-03-31 | — | — | EP | disclosed |
| US-7608731-B2 | Phenylacetic acid compounds | ROCHE PALO ALTO LLC (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608731-B2 | Phenylacetic acid compounds | ROCHE PALO ALTO LLC (US) | 2009-10-27 | — | — | US | disclosed |
| WO-2008157330-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008154271-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008154271-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080108810-A1 | Phenylacetic acid compounds | ROCHE PALO ALTO LLC | 2008-05-08 | — | — | US | disclosed |
| US-20080108810-A1 | Phenylacetic acid compounds | ROCHE PALO ALTO LLC | 2008-05-08 | — | — | US | disclosed |
| US-7291729-B2 | Process for preparing 3-aryloxy-phenylacetic acid compounds | ROCHE PALO ALTO LLC (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291729-B2 | Process for preparing 3-aryloxy-phenylacetic acid compounds | ROCHE PALO ALTO LLC (US) | 2007-11-06 | — | — | US | disclosed |
| US-7189718-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1737827-A1 | PROCESS FOR PREPARING PYRIDAZINONE COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005100323-A1 | PROCESS FOR PREPARING PYRIDAZINONE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-27 | — | — | WO | disclosed |
| US-20050234236-A1 | Process for preparing pyridazinone compounds | ROCHE PALO ALTO LLC | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108810-A1 | Phenylacetic acid compounds | CYP2A6, CYP2B6, DDC | VCAM1 3914/4885MERTK 3558/4885CYP3A4 100/4885 |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | SAMHD1, POLRMT, NUDT1 | VCAM1 1504/4885MERTK 3920/4885CYP3A4 169/4885 |
| US-20050234236-A1 | Process for preparing pyridazinone compounds | CYP2A6, CYP2B6, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | VCAM1 4001/4885MERTK 3137/4885CYP3A4 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.